Emergent BioSolutions Provides Corporate Governance Update
March 23, 2022 16:05 ET
|
Emergent BioSolutions
Zsolt Harsanyi, Ph.D. Appointed Chairman of the BoardKeith Katkin Appointed to the BoardEliminates Role of Executive ChairmanAppoints New Chairs of Audit, Strategic Operations, and Scientific Review...
Emergent BioSolutions to Participate in Investor Conferences
March 14, 2022 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
March 11, 2022 06:34 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety,...
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
February 24, 2022 16:05 ET
|
Emergent BioSolutions
Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidanceUpdates full year 2022...
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
February 07, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the...
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
January 14, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April...
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
January 09, 2022 14:00 ET
|
Emergent BioSolutions
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA...
Emergent BioSolutions to Participate in Investor Conferences
January 03, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
December 16, 2021 07:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...
Emergent BioSolutions Announces Stock Repurchase Program
November 11, 2021 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized management to repurchase up to $250 million of...